Clinical evaluation of a new live measles vaccine derived in chick chorioallantoic membranes

Neal A. Halsey, Leonard B. Weiner, Martin G. Meyers, Kenneth L. Herrmann, Alan Hinman

Research output: Contribution to journalArticlepeer-review

Abstract

A new measles vaccine (CAM) prepared in chick chorioallantoic membranes was compared with the routinely used measles vaccine (Attenuvax, Merck, Sharpe and Dohme) prepared in chick embryo tissue culture for immunogenicity and adverse reactions in 77 children. Recipients of the CAM vaccine developed significantly (P = 0·001) higher hemagglutination-inhibition (HI) geometric mean antibody titers (83·3 v. 42·8) than did recipients of Attenuvax. CAM vaccine recipients also experienced significantly (P < 0·01) higher rates of fever and rash in the period 6-15 days after vaccination. Although the CAM vaccine was more immunogenic than Attenuvax, the higher rates of fever and rash make the vaccine unacceptable for routine primary vaccination of children.

Original languageEnglish (US)
Pages (from-to)507-511
Number of pages5
JournalJournal of Biological Standardization
Volume9
Issue number4
DOIs
StatePublished - Oct 1981
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Clinical evaluation of a new live measles vaccine derived in chick chorioallantoic membranes'. Together they form a unique fingerprint.

Cite this